Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Gang Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6713-1185; OpenAlex author ID A5073844760, A5123380343. Sources: OpenAlex.

Their work

Papers
70 (first author 3, last author 35)
Trials
0
Grants
0
Labs led
2
Collaborators
161
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 7 papers · 2020: 6 papers · 2021: 8 papers · 2022: 7 papers · 2023: 9 papers · 2024: 5 papers · 2025: 9 papers · 2026: 8 papers

Papers 50 of 70

  1. The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. Last author DOI 10.1016/j.canlet.2026.218252↗
  2. Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy" [Cancer Lett. (202… Last author DOI 10.1016/j.canlet.2026.218298↗
  3. KRAS G12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.10.003↗
  4. Rewiring metabolic-immune circuitry in pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1016/j.cpt.2026.05.001↗
  5. ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. Last author DOI 10.1016/j.isci.2026.117479↗
  6. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Last author DOI 10.1016/j.ymthe.2026.03.012↗
  7. Early-Onset Pancreatic Ductal Adenocarcinoma: Clinical Features, Genomic Landscape, and Treatment-Mediated Survival Advantage Last author DOI 10.21203/rs.3.rs-9647757/v1↗
  8. [Clinical value of secondary surgical resection for recurrent or metastatic pancreatic cancer after initial surgery]. Last author DOI 10.3760/cma.j.cn112139-20250730-00378↗
  9. Menin regulates YBX1 nucleus translocation to boost the HKDC1 transcription and affects pancreatic cancer glycolysis. Co-author DOI 10.1016/j.isci.2025.113245↗
  10. A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy. Co-author DOI 10.1016/j.stem.2025.07.008↗
  11. Transcriptomic profiling of blood platelets identifies a diagnostic signature for pancreatic cancer. Co-author DOI 10.1038/s41416-025-02980-z↗
  12. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Last author DOI 10.1038/s41467-025-57520-3↗
  13. Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer. Co-author DOI 10.1038/s41467-025-61890-z↗
  14. Germline mutations and pancreatic cancer risk in chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2024-334277↗
  15. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Last author DOI 10.1172/jci.insight.181873↗
  16. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Last author DOI 10.1186/s12885-025-15341-z↗
  17. A mitochondria-related gene-based signature predicts pancreatic ductal adenocarcinoma clinical outcome and revealed CAMK2A/THEM4 regulates progression phenotyp… Last author DOI 10.1186/s12967-025-07456-5↗
  18. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13643↗
  19. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  20. Functional characteristics of DNA N6-methyladenine modification based on long-read sequencing in pancreatic cancer. Co-author DOI 10.1093/bfgp/elad021↗
  21. Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between CA19-9 (+) and CA19-9 (-) PDAC. Co-author DOI 10.1097/cm9.0000000000003130↗
  22. [Arterial prophylactic occlusion technique in the application of surgery for locally advanced pancreatic cancer with arterial involvement after conversion ther… Last author DOI 10.3760/cma.j.cn112139-20240415-00185↗
  23. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upf… Last author DOI 10.1016/j.asjsur.2022.09.156↗
  24. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Last author DOI 10.1016/j.xcrm.2023.101162↗
  25. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Co-author DOI 10.1038/s41591-023-02640-w↗
  26. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Last author DOI 10.1093/bjs/znac457↗
  27. A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohor… Last author DOI 10.1097/js9.0000000000000648↗
  28. Deep Learning for Fully Automated Prediction of Overall Survival in Patients Undergoing Resection for Pancreatic Cancer: A Retrospective Multicenter Study. Co-author DOI 10.1097/sla.0000000000005465↗
  29. Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery. Last author DOI 10.1186/s12893-023-02256-4↗
  30. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-2856912/v1↗
  31. [Establishment of the quality assessment system for pancreatic cancer surgery: from "single complication assessment" to "textbook outcome"]. Last author DOI 10.3760/cma.j.cn112139-20230308-00097↗
  32. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(22)00066-3↗
  33. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Co-author DOI 10.1038/s41467-022-29857-6↗
  34. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohisto… Co-author DOI 10.1097/mpa.0000000000002175↗
  35. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Co-author DOI 10.1186/s12916-022-02647-z↗
  36. Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40644-021-00443-1↗
  37. LINC00483 promotes proliferation and metastasis through the miR-19a-3p/TBK1/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.21037/atm-22-907↗
  38. Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma. Last author DOI 10.7150/jca.52943↗
  39. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Last author DOI 10.1002/ctm2.520↗
  40. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imagin… Co-author DOI 10.1016/j.media.2021.102150↗
  41. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Co-author DOI 10.1016/s1470-2045(21)00286-2↗
  42. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Co-author DOI 10.1038/s42003-021-02557-5↗
  43. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-021-08380-9↗
  44. Which Factors Are Associated with Positive Resection Margin in Pancreatic Ductal Adenocarcinoma for different surgical procedures? Results Based on a Standard … Last author DOI 10.21203/rs.3.rs-111309/v2↗
  45. Risk Factors of Positive Resection Margin Differ in Pancreaticoduodenectomy and Distal Pancreatosplenectomy For Pancreatic Ductal Adenocarcinoma: A Study Based… Last author DOI 10.21203/rs.3.rs-963631/v1↗
  46. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Last author DOI 10.3389/fonc.2021.717989↗
  47. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for… Last author DOI 10.1016/j.surg.2020.02.013↗
  48. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Last author DOI 10.1038/s41416-019-0704-2↗
  49. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  50. Genome-Wide Analysis of Cell-Free DNA Methylation Profiling for the Early Diagnosis of Pancreatic Cancer. Co-author DOI 10.3389/fgene.2020.596078↗

Closest collaborators

The 25 strongest of 161 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiwei Guo · 33 shared papers, 2014–2026 · strength 4.74
  2. Suizhi Gao · 26 shared papers, 2019–2026 · strength 3.70
  3. Xiaohan Shi · 24 shared papers, 2019–2026 · strength 3.58
  4. Xiaoyi Yin · 15 shared papers, 2021–2026 · strength 2.84
  5. Kailian Zheng · 18 shared papers, 2015–2026 · strength 2.79
  6. Xiongfei Xu · 12 shared papers, 2020–2026 · strength 1.91
  7. Guoxiao Zhang · 8 shared papers, 2021–2026 · strength 1.39
  8. Bo Li · 10 shared papers, 2020–2023 · strength 1.33
  9. Yunguang Li · 7 shared papers, 2022–2026 · strength 1.19
  10. Lingyu Zhu · 6 shared papers, 2023–2026 · strength 1.18
  11. Bin Song · 12 shared papers, 2012–2025 · strength 1.09
  12. Gang Li · 9 shared papers, 2015–2025 · strength 1.08
  13. Yehan Zhang · 6 shared papers, 2022–2026 · strength 1.08
  14. Dong Gao · 6 shared papers, 2022–2026 · strength 1.04
  15. Chenming Ni · 6 shared papers, 2019–2025 · strength 0.96
  16. Xiaoyi Yin · 2 shared papers, 2026 · strength 0.90
  17. Huan Wang · 3 shared papers, 2026 · strength 0.82
  18. Shuo Shen · 6 shared papers, 2019–2023 · strength 0.72
  19. Zhuo Shao · 8 shared papers, 2012–2023 · strength 0.70
  20. Kai Cao · 6 shared papers, 2019–2023 · strength 0.69
  21. Meilong Shi · 3 shared papers, 2026 · strength 0.59
  22. Jing Shen · 5 shared papers, 2019–2021 · strength 0.57
  23. Hui Jiang · 6 shared papers, 2012–2023 · strength 0.57
  24. Wenyu Liu · 3 shared papers, 2021–2022 · strength 0.48
  25. Gang Nie · 2 shared papers, 2022–2025 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.